FGFR2 loss sensitizes MYCN‐amplified neuroblastoma CHP134 cells to CHK1 inhibitor–induced apoptosis-Reference-Cited by-同舟云学术

FGFR2 loss sensitizes MYCN‐amplified neuroblastoma CHP134 cells to CHK1 inhibitor–induced apoptosis

Published:2021-11-30 Issue:2 Volume:113 Page:587-596
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Science

Author:

Ando Kiyohiro¹²³⁴^ORCID,Ohira Miki¹^ORCID,Takada Ichiro⁵,Cázares‐Ordoñez Verna⁵,Suenaga Yusuke³,Nagase Hiroki³^ORCID,Kobayashi Shinichi⁴,Koshinaga Tsugumichi⁶,Kamijo Takehiko¹,Makishima Makoto⁵,Wada Satoshi²⁴^ORCID

Affiliation:

1. Research Institute for Clinical Oncology Saitama Cancer Center Saitama Japan

2. Department of Clinical Diagnostic Oncology Showa University Clinical Research Institute for Clinical Pharmacology and Therapeutics Tokyo Japan

3. Chiba Cancer Center Research Institute Chiba Japan

4. Showa University Clinical Research Institute for Clinical Pharmacology and Therapeutics Tokyo Japan

5. Division of Biochemistry Department of Biomedical Sciences Nihon University School of Medicine Tokyo Japan

6. Department of Pediatric Surgery Nihon University School of Medicine Tokyo Japan

Funder

Japan Society for the Promotion of Science

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.15205

Reference47 articles.

1. The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report

2. The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report

3. Advances in Risk Classification and Treatment Strategies for Neuroblastoma

4. Neuroblastoma

5. Novel regions of chromosomal loss in familial neuroblastoma by comparative genomic hybridization

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibition;Proceedings of the National Academy of Sciences;2023-12-28

2. ALK signalling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibition;2023-09-04

3. Combination drug screen targeting glioblastoma core vulnerabilities reveals pharmacological synergisms;eBioMedicine;2023-09

4. DNA Ligase 4 Contributes to Cell Proliferation against DNA-PK Inhibition in MYCN-Amplified Neuroblastoma IMR32 Cells;International Journal of Molecular Sciences;2023-05-19

5. Combination drug screen targeting glioblastoma core vulnerabilities reveals pharmacological synergisms;2022-12-16